Glushchenko S. Optimization the Diagnosis and Treatment of Non-Alcoholic Steatohepatitis in Patients with Diabetes Mellitus Type 2 by Examining Markers of Mitochondrial Dysfunction

The thesis presents a study on the clinical and pathogenic role of L-carnitine, homocysteine, tumor necrosis factor ?, interleukin 6, nitrogen oxide, and malondialdehyde in the formation and progression of non-alcoholic steatohepatitis in patients diagnosed with diabetes mellitus type 2, thus contributing to the further development of early non-alcoholic steatohepatitis diagnosis prognosis methods. The pathogenic role of L-carnitine, homocysteine, tumor necrosis factor ?, interleukin 6, nitrogen oxide, and malondialdehyde in the development of cytolysis syndrome and dyslipidemia; the effect of homocysteine on the development of non-alcoholic steatohepatitis has been demonstrated; the extent of hyperhomocysteinemia has been proved to be related to the progression of liver dysmetabolism with an isolated course of non-alcoholic steatohepatitis as well as in combination with diabetes mellitus type 2. A comprehensive study on the anti-inflammatory cytokine rate and some lipid peroxidation system in patients with non-alcoholic steatohepatitis and those diagnosed with both non-alcoholic steatohepatitis and diabetes mellitus type 2 has been carried out. The role of the proinflammatory cytokine as inflammatory response markers has been identified, which can be an additional criterion for inflammation degree assessment in patients with non-alcoholic steatohepatitis. Impaired L-carnitine and homocysteine metabolism has been proven to be related to the proinflammatory cytokine rate in patients with non-alcoholic steatohepatitis and those diagnosed with both non-alcoholic steatohepatitis and diabetes mellitus type 2. A pathogenically substantiated comprehensive treatment for patients suffering from non-alcoholic steatohepatitis combined with diabetes mellitus type 2 has been developed that involves L-carnitine, deproteinized calf blood hemoderivative, and folic acid, which has a beneficial effect on the clinical course of the disease, eliminating carnitine deficiency, helping normalize the homocysteine rate, and presenting immune correction and an antioxidation effect.